Approach to prostate cancer in men older than 75 years: Active or passive?;Umgang mit dem Prostatakarzinom bei über 75-jährigen Männern: Aktiv oder passiv?

Urologe - Ausgabe A

Volumn 51, Issue 10, 2012, Pages 1368-1374

  Spahn, M ^a   Haeni, K ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Comorbidities; Overdiagnosis; Overtreatment; Prostate cancer; PSA screening

Indexed keywords

AGING; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; COMORBIDITY; ELDERLY CARE; HIGH RISK PATIENT; HUMAN; PERSONALIZED MEDICINE; PROSTATE CANCER; QUALITY OF LIFE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMORBIDITY; GERMANY; HUMANS; MALE; PATIENT SELECTION; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84867954558     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-012-3011-6     Document Type: Article

References (22)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
2. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN Int J Cancer 127:2893-2917
3. Ries L et al (2008) SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute. Available at: http://seercancergov/csr/1975- 2005/2008
4. Droz JP, Balducci L, Bolla M et al (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106:462-469
5. USPSTF (2012) US Preventive Service Task Force (USPSTF) recommendation on Screening for Prostate Cancer. http://www.uspreventiveservicestaskforceorg/ uspstf/
6. Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285:2750-2756
7. Fuchs J, Busch M, Lnge C et al (2002) Gender-sensitive public health publications in Germany? Results of a review of literature. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55:576-586
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
9. Rockwood K, Stadnyk K, MacKnight C et al (1999) A brief clinical instrument to classify frailty in elderly people. Lancet 353:205-206
10. Katz S, Ford AB, Moskowitz RW et al (1963) Studies of Illness in the Aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA 185:914-919
11. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179-186
12. Blanc-Bisson C, Fonck M, Rainfray M et al (2008) Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol 67:243-254
13. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095- 2101
14. Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209
15. Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708-1717
16. Richstone L, Bianco FJ, Shah HH et al (2008) Radical prostatectomy in men aged (or(70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 101:541-546
17. Manton KG, Vaupel JW (1995) Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 333:1232-1235
18. Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29:235-241
19. Albertsen PC, Moore DF, Shih W et al (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29:1335-1341
20. Studer UE, Whelan P, Albrecht W et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24:1868-1876
21. Studer UE, Collette L, Whelan P et al (2008) Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53:941-949
22. Lowrance WT, Elkin EB, Yee DS et al (2012) Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int 109:1309-1314